Cargando…

Value of AFP and PIVKA-II in diagnosis of HBV-related hepatocellular carcinoma and prediction of vascular invasion and tumor differentiation

BACKGROUND: To explore the value of alpha fetoprotein (AFP) and protein induced by vitamin K absence or antagonist-II (PIVKA-II) in diagnosis of HBV-related hepatocellular carcinoma (HCC) and their relationship with vascular invasion, tumor differentiation and size. METHODS: A total of 433 participa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Si, Yuan-Quan, Wang, Xiu-Qin, Fan, Gang, Wang, Chang-Yin, Zheng, Yuan-Wen, Song, Xie, Pan, Cui-Cui, Chu, Fu-Lu, Liu, Zhan-Feng, Lu, Bing-Ru, Lu, Zhi-Ming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7684907/ https://www.ncbi.nlm.nih.gov/pubmed/33292429 http://dx.doi.org/10.1186/s13027-020-00337-0

Ejemplares similares

The diagnostic value of PIVKA‐II, AFP, AFP‐L3, CEA, and their combinations in primary and metastatic hepatocellular carcinoma
por: Qi, Famei, et al.
Publicado: (2019)

Usefulness of AFP, AFP-L3, and PIVKA-II, and their combinations in diagnosing hepatocellular carcinoma
por: Park, Sang Joon, et al.
Publicado: (2017)

The value of PIVKA-Ⅱ versus AFP for the diagnosis and detection of postoperative changes in hepatocellular carcinoma
por: Lee, Qiuyan, et al.
Publicado: (2021)

Clinical value of serum AFP and PIVKA‐II for diagnosis, treatment and prognosis of hepatocellular carcinoma
por: Tian, Shan, et al.
Publicado: (2022)

The Diagnostic Value of Serum PIVKA-II Alone or in Combination with AFP in Chinese Hepatocellular Carcinoma Patients
por: Xu, Fei, et al.
Publicado: (2021)

Validation of combined AFP, AFP-L3, and PIVKA II for diagnosis and monitoring of hepatocellular carcinoma in Chinese patients
por: Ren, Tianying, et al.
Publicado: (2023)

PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma
por: Feng, Honglei, et al.
Publicado: (2021)

Performance evaluation of the Elecsys PIVKA‐II and Elecsys AFP assays for hepatocellular carcinoma diagnosis
por: Chan, Henry L Y, et al.
Publicado: (2022)

Diagnostic Performance of AFP, AFP-L3, or PIVKA-II for Hepatitis C Virus-Associated Hepatocellular Carcinoma: A Multicenter Analysis
por: Liu, Siyu, et al.
Publicado: (2022)

Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region
por: Kim, Do Young, et al.
Publicado: (2023)

The diagnostic performance of AFP and PIVKA-II models for non-B non-C hepatocellular carcinoma
por: Tran, Vinh Thanh, et al.
Publicado: (2023)

Utility of PIVKA-II and AFP in Differentiating Hepatocellular Carcinoma from Non-Malignant High-Risk Patients
por: Hadi, Hana, et al.
Publicado: (2022)

PIVKA-II or AFP has better diagnostic properties for hepatocellular carcinoma diagnosis in high-risk patients
por: Suttichaimongkol, Tanita, et al.
Publicado: (2023)

Clinical Significance of AFP and PIVKA-II Responses for Monitoring Treatment Outcomes and Predicting Prognosis in Patients with Hepatocellular Carcinoma
por: Park, Hana, et al.
Publicado: (2013)

Effect of PIVKA‐II and AFP secretion status on early recurrence of hepatocellular carcinoma after open and laparoscopic surgery
por: Cai, Yunshi, et al.
Publicado: (2023)

PIVKA-II level is correlated to development of portal vein tumor thrombus in patients with HBV-related hepatocellular carcinoma
por: Li, Tao, et al.
Publicado: (2019)

Diagnostic value of prothrombin induced by the absence of vitamin K or antagonist-II (PIVKA-II) for early stage HBV related hepatocellular carcinoma
por: Wang, Xiumei, et al.
Publicado: (2017)

Methylated SEPT9 combined with AFP and PIVKA-II is effective for the detection of HCC in high-risk population
por: Zheng, Kepu, et al.
Publicado: (2023)

Combination of IL-34 and AFP improves the diagnostic value during the development of HBV related hepatocellular carcinoma
por: Liu, Kehui, et al.
Publicado: (2022)

Reductions in AFP and PIVKA-II can predict the efficiency of anti-PD-1 immunotherapy in HCC patients
por: Sun, Xuqi, et al.
Publicado: (2021)

Impact of PIVKA-II in diagnosis of hepatocellular carcinoma
por: Zakhary, Nadia I., et al.
Publicado: (2013)

Serum GP73 is complementary to AFP and GGT-II for the diagnosis of hepatocellular carcinoma
por: HOU, SI-CONG, et al.
Publicado: (2013)

Diagnostic and Prognostic Nomograms for Hepatocellular Carcinoma Based on PIVKA-II and Serum Biomarkers
por: An, Shu, et al.
Publicado: (2023)

Real impact of tumor marker AFP and PIVKA-II in detecting very small hepatocellular carcinoma (≤ 2 cm, Barcelona stage 0) - assessment with large number of cases
por: Tarao, Kazuo, et al.
Publicado: (2020)

An Efficient Nomogram for Discriminating Intrahepatic Cholangiocarcinoma From Hepatocellular Carcinoma: A Retrospective Study
por: Si, Yuan-Quan, et al.
Publicado: (2022)

Diagnostic Value of hTERT mRNA and in Combination With AFP, AFP-L3%, Des-γ-carboxyprothrombin for Screening of Hepatocellular Carcinoma in Liver Cirrhosis Patients HBV or HCV-Related
por: Nguyen, Hoang Bac, et al.
Publicado: (2022)

Combination of inflammatory score/liver function and AFP improves the diagnostic accuracy of HBV‐related hepatocellular carcinoma
por: Ding, Yezhou, et al.
Publicado: (2020)

A Logistic Regression Model for Noninvasive Prediction of AFP-Negative Hepatocellular Carcinoma
por: Luo, Chang-Liang, et al.
Publicado: (2019)

TEMs but not DKK1 could serve as complementary biomarkers for AFP in diagnosing AFP-negative hepatocellular carcinoma
por: Mao, Liping, et al.
Publicado: (2017)

Identification of the Best Cut-Off Value of PIVKA-II for the Surveillance of Patients at Risk of Hepatocellular Carcinoma Development
por: Caviglia, Gian Paolo, et al.
Publicado: (2023)

Novel Value of Preoperative Gamma-Glutamyltransferase Levels in the Prognosis of AFP-Negative Hepatocellular Carcinoma
por: Lu, Liang-He, et al.
Publicado: (2020)

Clinical evaluation of Elecsys PIVKA-II for patients with advanced hepatocellular carcinoma
por: Kaneko, Shun, et al.
Publicado: (2022)

Preoperative color Doppler ultrasonography predicts early recurrence in AFP-positive hepatocellular carcinoma
por: Chen, Miao, et al.
Publicado: (2019)

The predictive value of the modified AFP model for liver transplantation outcomes in multinodular hepatocellular carcinoma patients
por: Wang, Jingrui, et al.
Publicado: (2023)

Simple Clinical Metrics Enhance AFP to Effectively Identify Cirrhotic Patients With Complicating Hepatocellular Carcinoma at Various AFP Levels
por: Zhang, Xi, et al.
Publicado: (2020)

Usefulness of PIVKA-II for monitoring after liver transplantation in patients with hepatocellular carcinoma
por: Villalba-López, Francisco, et al.
Publicado: (2023)

Changes and Clinical Significance of PIVKA-II in Hepatitis E Patients
por: Chen, Youran, et al.
Publicado: (2022)

PLCE1 polymorphisms and expression combined with serum AFP level predicts survival of HBV-related hepatocellular carcinoma patients after hepatectomy
por: Liao, Xiwen, et al.
Publicado: (2017)

Effectiveness of PIVKA-II in the detection of hepatocellular carcinoma based on real-world clinical data
por: Yu, Rentao, et al.
Publicado: (2017)

Better performance of PIVKA-II for detecting hepatocellular carcinoma in patients with chronic liver disease with normal total bilirubin
por: Qian, Xiang-Jun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_c3bg3u3uj04vqb6lstqu5u2vao